Literature DB >> 4827106

Surgical reduction of tumour bulk in management of abdominal Burkitt's lymphoma.

I T Magrath, S Lwanga, W Carswell, N Harrison.   

Abstract

The results of a retrospective study of the value of reductive surgery in the treatment of abdominal Burkitt's lymphoma are reported. Nine patients had almost complete removal of the tumour, 16 had little over half of the tumour removed, and 43 underwent biopsy only. All patients subsequently received chemotherapy. There was a highly significant difference in the proportion of patients achieving a sustained durable remission (P > 0.0001) and a significant difference in survival (P > 0.05) between the group having almost complete removal and the partial resection group. Partial resection gave no advantage over no surgery. We believe that whenever possible complete removal of the abdominal tumour should be attempted regardless of the presence of extra-abdominal tumour; but unless at least 90% of the tumour can be removed there is no advantage in partial resection in terms of response to subsequent chemotherapy. In particular the removal of one of two involved ovaries can no longer be recommended. The implications of these results are related to cancer treatment strategy.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4827106      PMCID: PMC1610975          DOI: 10.1136/bmj.2.5914.308

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  14 in total

1.  HOMOLOGOUS TUMOUR GROWTH IN METHYLCHOLANTHRENE-INDUCED SARCOMA-BEARING MICE.

Authors:  M MATSUYAMA; T NAKAMURA
Journal:  Nature       Date:  1964-04-11       Impact factor: 49.962

2.  A comparative study of the incidence of anergy in patients with carcinoma, leukemia, hodgkin's disease and other lymphomas.

Authors:  D LAMB; F PILNEY; W D KELLY; R A GOOD
Journal:  J Immunol       Date:  1962-10       Impact factor: 5.422

3.  Survival of skin homografts in methylcholanthrene-treated mice and in mice with spontaneous mammary cancers.

Authors:  O E LINDER
Journal:  Cancer Res       Date:  1962-04       Impact factor: 12.701

4.  Intensive chemotherapy in patients with generalized Burkitt's lymphoma.

Authors:  J L Ziegler; A Z Bluming; I T Magrath; P P Carbone
Journal:  Int J Cancer       Date:  1972-09-15       Impact factor: 7.396

5.  Single versus multiple dose dactinomycin therapy of Wilms's tumor. A controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A).

Authors:  J A Wolff; W A Newton; W Krivit; G J D'Angio
Journal:  N Engl J Med       Date:  1968-08-08       Impact factor: 91.245

Review 6.  Experimental studies in tumor imminology.

Authors:  G Klein
Journal:  Fed Proc       Date:  1969 Nov-Dec

7.  Chemotherapy of Burkitt's lymphoma.

Authors:  J L Ziegler
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

8.  Relapse patterns in Burkitt's lymphoma.

Authors:  J L Ziegler; A Z Bluming; L Fass; R H Morrow
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

9.  Survival of Burkitt's lymphoma patients in Mulago Hospital, Uganda.

Authors:  R H Morrow; M C Pike; A Kisuule
Journal:  Br Med J       Date:  1967-11-11

10.  Intrathecal chemotherapy in Burkitt's lymphoma.

Authors:  J L Ziegler; A Z Bluming
Journal:  Br Med J       Date:  1971-08-26
View more
  17 in total

1.  Adult ileocolic intussusception caused by Burkitt lymphoma.

Authors:  Daniele Bernardi; Emanuele Asti; Luigi Bonavina
Journal:  BMJ Case Rep       Date:  2016-12-05

2.  Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Authors:  K S Tewari; J J Java; R N Eskander; B J Monk; R A Burger
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

3.  Gastrointestinal tumors in children: an analysis of 39 cases.

Authors:  M A Skinner; D A Plumley; J L Grosfeld; F J Rescorla; K W West; L R Scherer
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

4.  Failure of BCG immunostimulation to affect the clinical course of Burkitt's lymphoma.

Authors:  I T Magrath; J L Ziegler
Journal:  Br Med J       Date:  1976-03-13

5.  Gastrointestinal and oncologic outcomes of pediatric gastrointestinal lymphoma following upfront resection or biopsy of bowel masses.

Authors:  Mohd Yusran Othman; Huma Faiz Halepota; Yun Le Linn; York Tien Lee; Kenneth T E Chang; Summaiyya Hanum Ahamed; Joyce C M Lam; Rajat Bhattacharyya; Ah Moy Tan; Amos H P Loh
Journal:  Pediatr Surg Int       Date:  2021-05-08       Impact factor: 1.827

6.  Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.

Authors:  Twalib Ngoma; Melissa Adde; Muheez Durosinmi; Jessie Githang'a; Yetunde Aken'Ova; Jane Kaijage; Oluwagbemiga Adeodou; Jamilla Rajab; Biobele J Brown; Lorenzo Leoncini; Kikkeri Naresh; Martine Raphael; Nina Hurwitz; Patricia Scanlan; Ama Rohatiner; David Venzon; Ian Magrath
Journal:  Br J Haematol       Date:  2012-07-30       Impact factor: 6.998

7.  Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology.

Authors:  T A Lister; M H Cullen; R B Brearley; M E Beard; A G Stansfeld; J M Whitehouse; P F Wrigley; J M Ford; J S Malpas; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

8.  The role of surgery in the management of American Burkitt's lymphoma and its treatment.

Authors:  M M Kemeny; I T Magrath; M F Brennan
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

9.  When should surgical cytoreduction in advanced ovarian cancer take place?

Authors:  Igor E Martinek; Sean Kehoe
Journal:  J Oncol       Date:  2009-10-25       Impact factor: 4.375

10.  Intussusceptions as acute abdomen caused by Burkitt lymphoma: a case report.

Authors:  Faton T Hoxha; Shemsedin I Hashani; Avdyl S Krasniqi; Fisnik I Kurshumliu; Driton S Komoni; Shpresa M Hasimja; Mehmet Maxhuni
Journal:  Cases J       Date:  2009-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.